Cagrilintide

Test Reports

5 MG - CG0108A - 02/05/2025

10 MG - CG1FTJ - 11/07/2024

10 MG - 2ENED8L - 07/17/2024

5 MG - 3L3B7J8 - 07/03/2024

Properties

Cagrilintide Peptide Synopsis

Cagrilintide is a novel amylin analogue, a peptide found in the body that is released in conjunction with insulin. It has shown promise in treating obesity and type 2 diabetes in animal trials. This compound has also been studied for its potential benefits in liver conditions, such as alcohol-related liver disease, and cardiovascular diseases. While there has been speculation about its role in Alzheimer's, no specific research has been published on this topic. Trials have researched Cagrilintide and semaglutide together for treating obesity and type 2 diabetes. The two proteins work in tandem to provide powerful and sustained weight loss effects, according to numerous studies. While preclinical research suggests impressive therapeutic potential, limitations in human clinical trials point to the need for additional study on the efficacy and safety aspects.

Cagrilintide Peptide Research

Amylin, also referred to as islet amyloid polypeptide or IAPP, is a naturally occurring peptide that the pancreatic beta cells produce in conjunction with insulin. According to research, it is a crucial signaling molecule in the brain that generates satiety. Amylin is produced as an 89 amino acid propeptide with a roughly 100:1 ratio to insulin. Amylin undergoes the same processing as insulin to provide a smaller active molecule with only 37 amino acids.

Amylin has multiple impacts, such as postponing stomach emptying, augmenting satiety in the brain, and decreasing glucose spikes after meals. Essentially, it postpones the spike in blood sugar levels after eating, aiding in the regulation of sugar utilization and promoting its conversion into energy rather than fat.

Amylin has demonstrated effects on bone metabolism and relationships with calcitonin and CGRP. These peptides function to decrease calcium levels in the blood by promoting its absorption in bone and may also impact the rate of calcium loss in the kidneys. The exact significance of this effect is currently uncertain. In summary, amylin can be seen as increasing bone deposition rates or protecting against bone degradation.

Cagrilintide is specifically engineered to resist the enzymes that degrade insulin, allowing it to have a longer half-life and more powerful and enduring effects. In animal trials where the amylin gene is silenced, this has led to decreased appetite and reduced calorie consumption, since amylin is broken down by the same enzymes.

The relationship between amylin and Alzheimer's disease may be linked through the occurrence of amyloid beta plaques. Too much amylin, often seen in cases of insulin resistance and diabetes, can lead to the formation of fibril which may interact with beta amyloid and contribute to the development of amyloid plaques. Although considered theoretical, this connection remains under investigation.